Results 21 to 30 of about 2,479 (207)

What's in the pipeline for pediatric headache treatment? [PDF]

Headache
Headache: The Journal of Head and Face Pain, Volume 66, Issue 2, Page 548-550, February 2026.
Gelfand AA, Szperka CL.
europepmc   +2 more sources

Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study

The Journal of Headache and Pain, 2021
Background Migraine prevalence is age and sex dependent, predominating in women in early and middle adulthood; however, migraine also represents a substantial burden for men and adults of all ages.
Antoinette MaassenVanDenBrink, Gisela M. Terwindt, Joshua M. Cohen, Steve Barash, Verena Ramirez Campos, Maja Galic, Xiaoping Ning, Mikko Kärppä   +7 more
doaj   +1 more source

Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study

The Journal of Headache and Pain, 2020
Background The long-term safety and efficacy of fremanezumab were evaluated in a 52-week extension study (NCT02638103). Patient satisfaction with fremanezumab, dosing preferences, and patient-reported outcomes were assessed in a subpopulation who ...
Dawn C. Buse, Sanjay K. Gandhi, Joshua M. Cohen, Verena Ramirez-Campos, Blaine Cloud, Ronghua Yang, Robert P. Cowan   +6 more
doaj   +1 more source

A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States

The Journal of Headache and Pain, 2022
Background Following approval of fremanezumab for the prevention of migraine in adults, health care decision makers are interested in understanding real-world clinical characteristics and treatment patterns among patients initiating fremanezumab therapy.
Lynda J. Krasenbaum, Vasantha L. Pedarla, Stephen F. Thompson, Krishna Tangirala, Joshua M. Cohen, Maurice T. Driessen   +5 more
doaj   +1 more source

Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index [PDF]

, 2022
Introduction: Assessing the impact of migraine preventive treatments on acute medication consumption is important in clinical evaluation. The number of acute medication intakes per each monthly migraine day (MMD) could provide insights on migraine burden
Caponnetto, Valeria, Čtrnáctá, Dana, Matoušová, Zuzana, Nežádal, Tomáš, Ornello, Raffaele, Sacco, Simona, Sette, Lucia, Šípková, Jitka   +7 more
core   +1 more source

Long-term treatment over 52 weeks with monthly fremanezumab in drug-resistant migraine. A prospective multicenter cohort study [PDF]

, 2023
Background: Real-world studies on fremanezumab, an anti-calcitonin gene-related peptide monoclonal antibody for migraine prevention, are few and with limited follow-up.
Allena, Marta, Baiata, Claudio, Baraldi, Carlo, Battistini, Stefania, Beretta, Natascia, Brovia, Daria, Burgalassi, Andrea, Caponnetto, Valeria, Casalena, Alfonsina, Castro, Flavia Lo, Chiarugi, Alberto, Coppola, Gianluca, Dalla Volta, Giorgio, De Cesaris, Francesco, De Icco, Roberto, De Tommaso, Marina, Fallacara, Adriana, Garascia, Gabriele, Gentile, Martino, Geppetti, Pierangelo, Granato, Antonio, Guerzoni, Simona, Iannone, Luigi Francesco, La Porta, Anna, Liaci, Giorgio, Mampreso, Edoardo, Manganotti, Paolo, Merlo, Paola, null, null, Onofri, Agnese, Ornello, Raffaele, Prudenzano, Maria Pia, Rainero, Innocenzo, Rebecchi, Valentina, Russo, Antonio, Sacco, Simona, Sances, Grazia, Sepe, Federica Nicoletta, Silvestro, Marcello, Tabasso, Giorgio, Tassorelli, Cristina, Tessitore, Alessandro, Tronci, Stefano, Vaghi, Gloria, Vigani, Giulia   +44 more
core   +1 more source

The Management of High-Frequency Episodic and Chronic Migraines with Calcitonin Gene-Related Peptide Monoclonal Antibody [PDF]

Анналы клинической и экспериментальной неврологии, 2023
Introduction. High prevalence of migraine and its impact on quality of life requires the development of original agents. In 2020, fremanezumab, a new calcitonin gene-related peptide monoclonal antibody was authorized in Russia.
Larisa A. Dobrynina, Maksim A. Afanasev, Anastasia V. Belopasova, Maria V. Gubanova, Ekaterina V. Baydina   +4 more
doaj   +1 more source

Visual hypersensitivity in patients treated with anti-calcitonin gene–related peptide (receptor) monoclonal antibodies [PDF]

, 2023
Objective: To evaluate the effect of treatment with anti-calcitonin gene–related peptide (CGRP; receptor) antibodies on visual hypersensitivity in patients with migraine.
Carpay, Johannes A., de Vries Lentsch, Simone, Maassen van den Brink, Antoinette, Perenboom, Matthijs J.L., Terwindt, Gisela M.   +4 more
core   +2 more sources

Fremanezumab [PDF]

pharma-kritik, 2020
Fremanezumab ist der dritte in der Schweiz erhältliche Hemmer des «Calcitonin Gene-Related Peptide» (CGRP). Diese Medikamente sind zur Prävention von Migräneanfällen zugelassen, bisher aber nicht mit anderen präventiven Massnahmen verglichen worden. Am besten werden sie deshalb vorläufig nur im Rahmen von Studien eingesetzt.
openaire   +1 more source

Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal [PDF]

, 2023
: Background: Few studies compare the clinical effectiveness of the three anti-CGRP mAbs. Moreover, no studies compare their efficacy during suspension and reprisal.
Belgrado, Enrico, Cellante, Giulia, Dal Bello, Simone, Del Regno, Caterina, Ercole, Bruno Hector, Ermanis, Giovanni, Gigli, Gian Luigi, Lettieri, Christian, Merlino, Giovanni, Pez, Sara, Sportelli, Giuseppe, Tereshko, Yan, Valente, Mariarosaria, Versace, Salvatore   +13 more
core   +1 more source